Olanzapine News and Research

RSS
Olanzapine (trade names Zyprexa, Zyprexa Zydis, Zalasta, Zolafren, Olzapin, Rexapin or in combination with fluoxetine Symbyax) is an atypical antipsychotic, approved by the FDA for the treatment of schizophrenia and bipolar disorder.
Eli Lilly to pay $1.415 billion for off-label promotion of Zyprexa

Eli Lilly to pay $1.415 billion for off-label promotion of Zyprexa

Lilly receives complete response letter for Olanzapine LAI for treatment of schizophrenia

Lilly receives complete response letter for Olanzapine LAI for treatment of schizophrenia

Study questions use of newer antipsychotic drugs in children

Study questions use of newer antipsychotic drugs in children

Newer atypical antipsychotic medications no better than older drug in treating child and adolescent schizophrenia

Newer atypical antipsychotic medications no better than older drug in treating child and adolescent schizophrenia

Antipsychotic drugs get FDA label changes

Antipsychotic drugs get FDA label changes

Spectral Modeling technology substantiated through creation of antipsychotic bank of drug candidates

Spectral Modeling technology substantiated through creation of antipsychotic bank of drug candidates

Treatment with an anti-psychotic drug found to cause changes in metabolism earlier than expected

Treatment with an anti-psychotic drug found to cause changes in metabolism earlier than expected

Aripiprazole has potential for treating alcohol dependence

Aripiprazole has potential for treating alcohol dependence

Lilly knocked back by FDA on Zyprexa for schizophrenia treatment

Lilly knocked back by FDA on Zyprexa for schizophrenia treatment

Treatment of children and adolescents with schizophrenia

Treatment of children and adolescents with schizophrenia

New schizophrenia treatment

New schizophrenia treatment

Novel and inexpensive tool for identifying early signs of schizophrenia

Novel and inexpensive tool for identifying early signs of schizophrenia

Little evidence to support therapies for post-traumatic stress disorder

Little evidence to support therapies for post-traumatic stress disorder

Review of PTSD treatments

Review of PTSD treatments

Urgent need for better understanding of bipolar disease in children and adolescents

Urgent need for better understanding of bipolar disease in children and adolescents

New and very different schizophrenia drug shows promise

New and very different schizophrenia drug shows promise

New treatments for migraines and chronic headaches

New treatments for migraines and chronic headaches

Chemical maps hint at drug's effects on schizophrenia

Chemical maps hint at drug's effects on schizophrenia

Lilly to extend patient assistance programs for Medicare patients

Lilly to extend patient assistance programs for Medicare patients

Olanzapine appears to lower or delay full-blown psychosis

Olanzapine appears to lower or delay full-blown psychosis

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.